145 related articles for article (PubMed ID: 24224632)
1. Survival in the prostate cancer prevention trial.
Tangen CM; Goodman PJ; Thompson IM
N Engl J Med; 2013 Nov; 369(20):1968. PubMed ID: 24224632
[No Abstract] [Full Text] [Related]
2. Survival in the prostate cancer prevention trial.
Revannasiddaiah S; Susheela SP
N Engl J Med; 2013 Nov; 369(20):1967. PubMed ID: 24224634
[No Abstract] [Full Text] [Related]
3. Survival in the prostate cancer prevention trial.
Walsh PC
N Engl J Med; 2013 Nov; 369(20):1967. PubMed ID: 24224633
[No Abstract] [Full Text] [Related]
4. Re: long-term survival of participants in the Prostate Cancer Prevention Trial.
Kaplan SA
J Urol; 2014 Feb; 191(2):359. PubMed ID: 24411852
[No Abstract] [Full Text] [Related]
5. Re: long-term survival of participants in the Prostate Cancer Prevention Trial.
Seftel AD
J Urol; 2014 Feb; 191(2):359. PubMed ID: 24411851
[No Abstract] [Full Text] [Related]
6. Re: long-term survival of participants in the Prostate Cancer Prevention Trial.
Taneja SS
J Urol; 2014 Feb; 191(2):358. PubMed ID: 24411850
[No Abstract] [Full Text] [Related]
7. [Prevention of prostate cancer. Long-term results of the Prostate Cancer Prevention Trial (PCPT)].
Michel MS; Nitschmann S; von Hardenberg J
Internist (Berl); 2014 Aug; 55(8):981-2. PubMed ID: 25027005
[No Abstract] [Full Text] [Related]
8. A role for finasteride in the prevention of prostate cancer?
LeFevre M
N Engl J Med; 2013 Aug; 369(7):670-1. PubMed ID: 23944306
[No Abstract] [Full Text] [Related]
9. Prostate cancer prevention with 5 alpha-reductase inhibitors.
Parekh DJ
Recent Results Cancer Res; 2011; 188():109-14. PubMed ID: 21253793
[No Abstract] [Full Text] [Related]
10. Few physicians prescribe 5-alpha reductase inhibitors for prostate cancer prevention.
Barton MK
CA Cancer J Clin; 2011; 61(1):1-2. PubMed ID: 21199914
[No Abstract] [Full Text] [Related]
11. Prostate cancer: mortality unaffected by finasteride treatment.
Payton S
Nat Rev Urol; 2013 Oct; 10(10):551. PubMed ID: 24018566
[No Abstract] [Full Text] [Related]
12. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
[No Abstract] [Full Text] [Related]
13. Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Goodman PJ; Tangen CM; Darke AK; Lucia MS; Ford LG; Minasian LM; Parnes HL; LeBlanc ML; Thompson IM
N Engl J Med; 2019 Jan; 380(4):393-394. PubMed ID: 30673548
[No Abstract] [Full Text] [Related]
14. Prostate cancer chemoprevention with 5α-reductase inhibitors.
Nepple KG; Andriole GL
Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
[No Abstract] [Full Text] [Related]
15. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of 5-alpha reductase inhibitors in chemoprevention.
White WM; Kim ED
Nat Rev Clin Oncol; 2010 Sep; 7(9):487-8. PubMed ID: 20798697
[No Abstract] [Full Text] [Related]
17. Long-term survival of participants in the prostate cancer prevention trial.
Silberstein JL; Sartor O
Asian J Androl; 2014; 16(3):413-4. PubMed ID: 24625877
[TBL] [Abstract][Full Text] [Related]
18. Prevention of prostate cancer with finasteride.
Schwartz DT
N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562808
[No Abstract] [Full Text] [Related]
19. Re: Long-term survival of participants in the Prostate Cancer Prevention Trial.
Thompson IM; Tangen CM; Goodman PJ
Asian J Androl; 2014; 16(3):414. PubMed ID: 24914438
[No Abstract] [Full Text] [Related]
20. Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer.
Reddy GK
Clin Prostate Cancer; 2004 Mar; 2(4):206-8. PubMed ID: 15072601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
